A clinical trial listing tied to bradykinin was updated on September 10, 2026. The study, registered as NCT04401436 and titled "COVID-19 Associated Lymphopenia Pathogenesis Study in Blood," changed status to completed.
No phase was specified in the registry entry for this study. The listing does not include results data as part of this status update. Bradykinin remains classified as an unapproved research compound, and this trial record does not change that status.
This update reflects only the administrative status change on ClinicalTrials.gov as of the listed date. No outcome measures, efficacy data, or safety findings were provided alongside this status change. The trial title indicates a focus on lymphopenia pathogenesis in the context of COVID-19, but the specific role of bradykinin within the study design was not detailed in the event data provided.
Readers should note that trial completion status alone does not indicate whether findings support, refute, or are neutral toward any hypothesis under investigation. Further details, including any published results, would need to be sourced directly from the trial registry or subsequent publications.
For more background on bradykinin, readers can consult the compound overview.